Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?
about
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United StatesComparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.Target-specific oral anticoagulants and the hospitalist.Designing and Implementing an Electronic Patient Registry to Improve Warfarin Monitoring in the Ambulatory Setting.A Bayesian dose-individualization method for warfarin.A prospective study on the use of warfarin in the United arab emirates.
P2860
Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?
@en
Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?
@nl
type
label
Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?
@en
Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?
@nl
prefLabel
Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?
@en
Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?
@nl
P2093
P2860
P1476
Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?
@en
P2093
P2860
P304
P356
10.1111/J.1365-2710.2011.01324.X
P577
2011-12-16T00:00:00Z